Carna Biosciences Past Earnings Performance

Past criteria checks 0/6

Carna Biosciences's earnings have been declining at an average annual rate of -32.7%, while the Life Sciences industry saw earnings growing at 24.8% annually. Revenues have been declining at an average rate of 12.5% per year.

Key information

-32.7%

Earnings growth rate

-28.1%

EPS growth rate

Life Sciences Industry Growth32.0%
Revenue growth rate-12.5%
Return on equity-56.9%
Net Margin-107.8%
Next Earnings Update10 Feb 2025

Recent past performance updates

Recent updates

Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Aug 06
Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Apr 17
What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Apr 11
Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Feb 17
How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?

Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Dec 26
Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?

Revenue & Expenses Breakdown

How Carna Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4572 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,401-1,5108171,903
30 Jun 241,440-1,3617111,903
31 Mar 241,579-1,0315301,903
31 Dec 231,625-1,1526641,903
30 Sep 231,002-1,7846671,882
30 Jun 231,047-1,8758161,882
31 Mar 231,058-1,8537761,882
31 Dec 221,386-1,3496031,882
30 Sep 222,476-1515881,841
30 Jun 222,426-1175021,841
31 Mar 222,340-2636001,841
31 Dec 212,017-5345721,841
30 Sep 21922-1,6409031,474
30 Jun 21984-1,4907881,474
31 Mar 211,029-1,2135461,474
31 Dec 201,133-1,1115241,474
30 Sep 201,192-9347171,281
30 Jun 201,326-7646961,281
31 Mar 203,3738808431,281
31 Dec 193,2078287411,281
30 Sep 193,0307256921,140
30 Jun 192,8154747021,140
31 Mar 19712-1,2525331,140
31 Dec 18754-1,2105081,140
30 Sep 18760-1,051842670
30 Jun 18730-910683670
31 Mar 18672-813554670
31 Dec 17657-737464670
30 Sep 17713-619535513
30 Jun 17695-572473513
31 Mar 17782-396449513
31 Dec 16811-289468513
30 Sep 16873-294607417
30 Jun 16877-243574417
31 Mar 161,460351502417
31 Dec 151,569456409417
30 Sep 151,428116240561
30 Jun 151,43977277561
31 Mar 15777-641364561
31 Dec 14611-846416561
30 Sep 14671-477504423
30 Jun 14736-388481423
31 Mar 14762-322441423

Quality Earnings: 4572 is currently unprofitable.

Growing Profit Margin: 4572 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4572 is unprofitable, and losses have increased over the past 5 years at a rate of 32.7% per year.

Accelerating Growth: Unable to compare 4572's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4572 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (1.4%).


Return on Equity

High ROE: 4572 has a negative Return on Equity (-56.9%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 12:28
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Carna Biosciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yen Ting ChenCredit Suisse